Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics
Invossa Affair Still Hangs Heavy
Executive Summary
South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.
You may also be interested in...
Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
Korea 2019 Review: Industry Spooked By Invossa Affair, Disappointing Trials But Hopes Intact
The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.
Gene And Cell Therapies In Asia: Indian Environment Evolving But Multiple Issues Unresolved
India has taken strides towards creating a supportive environment for its nascent gene therapy research, but the R&D and regulatory infrastructure is still evolving amid concerns over potential product costs.